RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different

A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non–small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non–small cell lung cancer and triple-negative breast cancer.

See related article by Jaeger-Ruckstuhl et al., p. XX.